- Medical Devices
- Pelvic Floor Diagnostics Market
Pelvic Floor Diagnostics Market Size, Share, and Growth Forecast 2026 - 2033
Pelvic Floor Diagnostics Market by Diagnostic Test (Ultrasound, MRI, Urodynamic Testing, Electromyography, Manometry, Others), Condition (Urinary Incontinence, Pelvic Organ Prolapse, Fecal Incontinence, Pelvic Pain, Others), End-User (Hospitals & Clinics, Diagnostic Centers, Specialty Clinics, Research Institutes), and Regional Analysis for 2026 - 2033
Pelvic Floor Diagnostics Market Size and Trends Analysis
The global pelvic floor diagnostics market is expected to be valued at US$ 2.2 billion in 2026 and is projected to reach US$ 3.2 billion by 2033, growing at a CAGR of 5.7% between 2026 and 2033.
The rising prevalence of pelvic floor disorders in aging and postpartum populations is a key factor driving the market growth, as accurate diagnosis is essential before conservative therapy, devices or surgery. A widely cited study in the BJU International estimated that more than 420 million people worldwide were living with urinary incontinence by 2018. In the U.S., research supported by the National Institutes of Health (NIH) found that nearly one in four women have at least one pelvic floor disorder, rising to about half of women aged 80 and older.
Growing awareness of women's health, improved reimbursement for urodynamic and imaging tests, and stricter preoperative evaluation following regulatory action on transvaginal mesh are boosting the market growth.
Key Industry Highlights
- Leading Region: North America is likely to lead the pelvic floor diagnostics market with about 36% share in 2026, supported by high awareness, established reimbursement, fellowship-trained specialists, and strong installed bases of urodynamic systems.
- Fastest-Growing Region: Asia Pacific represents the fastest-growing market, fueled by rapid aging in China and Japan, expanding urogynecology centers, and improving access to diagnostic imaging.
- Dominant Segment: Ultrasound is the leading diagnostic test segment, holding around 33% share in 2026, as non-invasive, radiation-free translabial, endoanal, and 3D/4D imaging is widely used to evaluate prolapse, sphincter injuries, and levator ani damage.
- Fastest-Growing Segment: Urodynamic testing is projected to grow at the fastest rate through 2033, driven by guideline-based preoperative evaluation, post-mesh safety reforms, and adoption of wireless, ambulatory, and AI-assisted systems.
- Key Market Opportunity: AI-enabled ultrasound, portable imaging and next-generation urodynamic systems integrated with postpartum care and digital women's health platforms offer strong growth potential for diagnostic manufacturers.

Market Dynamics
Drivers - Growing Prevalence of Pelvic Floor Disorders in Aging Populations
Population aging is significantly increasing the number of people who need pelvic floor evaluation. The World Health Organization (WHO) projects that One in six people worldwide is expected to be aged 60 or older by 2030, and pelvic floor disorders become far more common with age, menopause and declining muscle strength. In the U.S., the National Association for Continence (NAFC) estimates that about 25 million adults experience bladder leakage, while a study published in Obstetrics & Gynecology projected that the number of American women with at least one pelvic floor disorder is projected to rise from about 28 million in 2010 to nearly 44 million by 2050.
Fecal incontinence also affects around eight percent of U.S. adults according to data from the National Health and Nutrition Examination Survey (NHANES). As these patient pools expand, demand grows for ultrasound, urodynamic testing, manometry and electromyography to guide personalized treatment pathways.
Childbirth-Related Pelvic Floor Injury and Expanding Postpartum Care
Childbirth is one of the most important risk factors for pelvic floor damage, creating a large and recurring source of diagnostic demand. The United Nations estimates that more than 130 million babies are born each year, and research using translabial ultrasound has shown that levator ani muscle avulsion occurs in roughly 10% to 30% of women after vaginal delivery. The Royal College of Obstetricians and Gynaecologists (RCOG) reports that obstetric anal sphincter injuries occur in about three percent of vaginal births in the U.K., rising to around six percent among first-time mothers.
These injuries can lead to urinary and fecal incontinence and prolapse later in life. Health systems are responding with dedicated postpartum pelvic health services; for example, NHS England has committed to perinatal pelvic health services nationwide, and France reimburses perineal rehabilitation after childbirth. These programs increase referrals for endoanal ultrasound, manometry and pelvic floor assessments.
Restraints - Social Stigma, Underreporting and Low Diagnosis Rates
Embarrassment and limited awareness prevent many patients from seeking care, restricting diagnostic volumes. Studies published in peer-reviewed urology and gynecology journals consistently show that fewer than half of women with urinary incontinence discuss symptoms with a healthcare provider, and many assume leakage is a normal part of aging or motherhood. Fecal incontinence is even more underreported due to strong social stigma. Primary care physicians often lack time or training to screen for pelvic floor symptoms, and patients can be treated empirically with medications or pads without formal diagnostic testing.
In many low- and middle-income countries, cultural barriers and limited women's health services further reduce presentation rates. This diagnostic gap means a large share of the affected population never reaches specialized testing, limiting the use of urodynamic systems, imaging and manometry equipment despite high disease prevalence.
High Equipment Costs, Invasiveness and Specialist Shortages
Pelvic floor diagnostics depend on specialized equipment and trained clinicians, both of which are unevenly distributed. Multichannel urodynamic systems, high-resolution anorectal manometry platforms and 3D/4D ultrasound machines require substantial capital investment, while MRI defecography and dynamic pelvic MRI are expensive and available mainly in tertiary centers. Organisation for Economic Co-operation and Development (OECD) data show wide variation in MRI availability, with Japan reporting more than 50 MRI units per million people compared with far lower levels in many emerging economies.
Urodynamic testing is also invasive, requiring catheterization that some patients find uncomfortable and that carries a small risk of urinary tract infection. Furthermore, the number of fellowship-trained urogynecologists, colorectal specialists and pelvic health physiotherapists remains limited in many regions, leading to long waiting lists and restricting market expansion outside major urban hospitals.
Opportunities - Next-Generation Urodynamic Testing and Ambulatory Systems
Urodynamic testing, the fastest-growing diagnostic test segment, offers strong opportunities for manufacturers that improve comfort, accuracy and workflow. Clinical guidelines from the American Urological Association (AUA), the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) and the International Continence Society (ICS) define standards for urodynamic studies in complex incontinence, neurogenic bladder and pre-surgical evaluation. In the U.K., National Institute for Health and Care Excellence (NICE) guideline NG123 recommends urodynamic testing before surgery in women with mixed or unclear symptoms.
Following the U.S. Food and Drug Administration's (FDA) 2019 order halting sales of transvaginal mesh for prolapse repair and the U.K.'s Independent Medicines and Medical Devices Safety Review in 2020, clinicians are placing greater emphasis on thorough preoperative assessment. Manufacturers developing wireless, catheter-reduced, ambulatory and AI-assisted urodynamic systems with cloud-based reporting are well positioned to capture new installations in hospitals and specialty clinics.
AI-Enabled Imaging, Point-of-Care Ultrasound and Femtech Integration
Advances in imaging and digital health are opening new avenues for pelvic floor diagnostics beyond traditional hospital settings. Three- and four-dimensional translabial and transperineal ultrasound now allow clinicians to visualize levator ani injuries, prolapse and mesh complications without radiation, and artificial intelligence tools are being developed to automate measurements and reduce operator dependence. Portable and handheld ultrasound devices from manufacturers such as GE HealthCare, Philips and Butterfly Network are lowering costs and enabling use in physiotherapy clinics and community settings.
At the same time, the women's health technology sector is expanding, with connected pelvic floor trainers and biofeedback devices that generate data on muscle function and can trigger referrals for formal evaluation. Telehealth platforms that combine symptom questionnaires, remote consultations and home-based monitoring can identify patients earlier. Companies integrating imaging, software and digital follow-up into complete pelvic health pathways can build recurring revenue models and expand access.
Category-wise Analysis
Diagnostic Test Insights
Ultrasound is the leading diagnostic test segment, accounting for around 33% share of the pelvic floor diagnostics market in 2026. It is widely used for pelvic floor assessment because it is non-invasive, radiation-free, relatively affordable, and available in hospitals and clinics.
Translabial, transperineal, transvaginal, and endoanal ultrasound techniques evaluate bladder neck mobility, levator ani integrity, anal sphincter defects, and pelvic organ prolapse in real time, including during coughing and straining. Endoanal ultrasound is an established method for assessing anal sphincter injuries following childbirth, while 3D and 4D ultrasound technologies provide more detailed anatomical visualization. GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, and Mindray offer imaging systems and transducers used in pelvic assessment.
Urodynamic testing is projected to record the fastest CAGR between 2026 and 2033, supported by increasing demand for functional assessment before surgical interventions and growing adoption of ambulatory testing systems. These procedures evaluate bladder storage, urine flow, and emptying function, helping clinicians distinguish between different causes of urinary dysfunction. Rising diagnosis of complex urinary incontinence and the need for treatment-specific assessments are expected to support segment growth.
Condition Insights
Urinary incontinence represents the leading condition segment, holding around 41% of the market share in 2026. It is a common pelvic floor disorder, with stress, urge, and mixed incontinence representing major clinical categories recognized by the International Continence Society. In the United States, the National Association for Continence estimates that around 25 million adults experience bladder leakage, with women affected at higher rates due to factors including pregnancy, childbirth, and menopause.
Accurate diagnosis of the type and severity of incontinence helps clinicians select appropriate treatments, including pelvic floor muscle training, medications, neuromodulation, bulking agents, and sling procedures. This supports demand for urodynamic studies, bladder ultrasound, and electromyography.
Pelvic organ prolapse is projected to record the fastest CAGR through 2033, driven by aging populations and increasing demand for detailed anatomical and functional assessments. Imaging and pelvic floor evaluations help clinicians determine prolapse severity, identify associated structural abnormalities, and guide treatment planning. Growing awareness of pelvic health and increasing use of diagnostic assessments before surgical and non-surgical interventions are expected to support segment expansion.
End-User Insights
Hospitals & clinics represent the leading end-user segment, accounting for around 48% of the market share in 2026. These facilities provide access to multidisciplinary teams comprising urologists, urogynecologists, colorectal surgeons, radiologists, and physiotherapists. They also maintain specialized equipment for MRI defecography, multichannel urodynamics, and high-resolution anorectal manometry. Hospital outpatient departments commonly evaluate patients before prolapse and incontinence procedures, while teaching hospitals conduct complex diagnostic assessments and research studies.
Established reimbursement pathways for procedures such as complex cystometrograms and anorectal manometry further support adoption. In the U.K., multidisciplinary pelvic floor teams within NHS hospitals assess complex cases in accordance with relevant clinical guidance.
Specialty clinics are projected to record the fastest CAGR between 2026 and 2033, driven by the expansion of dedicated pelvic health centers, urogynecology practices, and pelvic floor physiotherapy clinics. These facilities increasingly adopt office-based diagnostic tools that support convenient assessment and follow-up. Growing demand for specialized pelvic health services, shorter appointment pathways, and coordinated diagnostic and rehabilitation programs is expected to support segment growth.

Regional Analysis
North America Pelvic Floor Diagnostics Market Trends and Insights
North America is expected to lead the global pelvic floor diagnostics market with about 36% share in 2026, supported by high disease awareness, advanced healthcare infrastructure and established reimbursement for urodynamic, imaging and manometry procedures. The region has a large population of fellowship-trained urogynecologists and urologists, supported by the subspecialty of Urogynecology and Reconstructive Pelvic Surgery certified by the American Board of Obstetrics and Gynecology and the American Board of Urology.
Key trends include growing use of office-based urodynamics, wider adoption of 3D/4D pelvic floor ultrasound, rising interest in postpartum pelvic health and digital women's health platforms.
Organizations such as the American Urogynecologic Society (AUGS) and SUFU promote clinical standards and awareness. The FDA's 2019 action on transvaginal mesh has also increased emphasis on accurate preoperative assessment, supporting sustained demand for advanced pelvic floor diagnostic technologies across hospitals and specialty clinics.
U.S. Pelvic Floor Diagnostics Market Size
The U.S. pelvic floor diagnostics market is estimated at about US$ 705 million in 2026. The country has a very large patient population, with the NAFC estimating 25 million adults living with bladder leakage and NHANES data indicating that around eight percent of adults experience fecal incontinence. NIH-supported research projects that nearly 44 million American women can have at least one pelvic floor disorder by 2050. Strong reimbursement under Centers for Medicare & Medicaid Services (CMS) coding for urodynamic studies and anorectal manometry supports utilization, while leading manufacturers such as Laborie Medical Technologies and Medtronic maintain extensive U.S. installed bases.
Growth in ambulatory surgery centers, women's health clinics and pelvic floor physiotherapy creates opportunities for compact, office-based diagnostic systems. Rising awareness campaigns and telehealth adoption are expected to bring more patients into formal diagnostic pathways through 2033.
Europe Pelvic Floor Diagnostics Market Trends and Insights
Europe is the second-largest market, supported by universal healthcare systems, strong clinical research in urogynecology and colorectal surgery, and well-established professional societies. The European Association of Urology (EAU) publishes widely used guidelines on urinary incontinence that include recommendations for urodynamic testing, while the International Urogynecological Association (IUGA) and the International Continence Society (ICS), headquartered in Europe, promote standardized diagnostic practice.
Key trends include multidisciplinary pelvic floor units, increased use of endoanal and 3D ultrasound, growing postpartum pelvic health services and stricter evaluation before prolapse surgery following mesh-related safety reviews.
Many European countries are also investing in women's health strategies that highlight pelvic floor disorders as a priority. The region's aging population, with the European Union reporting that over 21% of its population was aged 65 or older in 2023 according to Eurostat, ensures rising long-term demand for diagnostic services.
Germany Pelvic Floor Diagnostics Market Size
Germany’s market is estimated at US$ 140 million in 2026. The German Continence Society (Deutsche Kontinenz Gesellschaft) estimates that around nine million people in Germany live with incontinence, creating a large patient population. The society certifies continence and pelvic floor centers that bring together urologists, gynecologists, colorectal surgeons and physiotherapists, encouraging standardized diagnostic workflows including urodynamics, ultrasound and manometry. Germany's statutory health insurance system covers many diagnostic procedures, supporting broad access.
The country also has one of the oldest populations in Europe, with more than 22% of residents aged 65 or older according to the Federal Statistical Office (Destatis). A strong medical technology sector, including companies such as Andromeda Medizinische Systeme and Siemens Healthineers, supports local innovation and service, creating opportunities for advanced urodynamic and imaging solutions.
U.K. Pelvic Floor Diagnostics Market Size
The U.K. market is estimated at US$ 108 million in 2026. The National Health Service (NHS) estimates that between 3 million and 6 million people in the U.K. have some degree of urinary incontinence. Pelvic floor care has received significant policy attention following the Independent Medicines and Medical Devices Safety Review, published in July 2020, which examined harms associated with vaginal mesh and called for specialist mesh centers and better patient assessment. NICE guideline NG123 sets standards for evaluating urinary incontinence and prolapse in women, including urodynamics before certain surgeries.
NHS England has also committed to perinatal pelvic health services across the country, improving early identification of childbirth-related injuries. The RCOG and British Society of Urogynaecology (BSUG) promote training and audit. These policy initiatives create steady demand for ultrasound, urodynamic systems and anorectal physiology services across NHS trusts.
France Pelvic Floor Diagnostics Market Size
France’s pelvic floor diagnostics market is anticipated to reach US$ 102 million in 2026. The country is internationally recognized for its emphasis on postpartum pelvic floor care, with the national health insurance system, Assurance Maladie, reimbursing perineal rehabilitation sessions after childbirth. This approach increases awareness and encourages early assessment of pelvic floor function among women. The French Association of Urology (AFU) and the French National College of Gynecologists and Obstetricians (CNGOF) publish guidelines covering urinary incontinence and prolapse evaluation, supporting the use of urodynamic testing and imaging before surgery.
France's aging population, with more than 21% of residents aged 65 or older according to INSEE, further expands the patient pool. Growing numbers of specialized pelvic floor units in university hospitals and private clinics, combined with strong public reimbursement, create opportunities for advanced ultrasound, electromyography and urodynamic equipment suppliers across the country.
Asia Pacific Pelvic Floor Diagnostics Market Trends and Insights
Asia Pacific is projected to record the fastest CAGR between 2026 and 2033, driven by rapid population aging, improving healthcare infrastructure, rising awareness of women's health and growing medical device adoption. China is the region's largest growth engine; the National Bureau of Statistics of China reported that about 217 million people, or 15.4% of the population, were aged 65 or older in 2023. Chinese hospitals are expanding urogynecology and pelvic floor rehabilitation centers, and pelvic floor screening after childbirth has become increasingly common in major cities.
Key regional trends include growing use of pelvic floor ultrasound, expansion of urodynamic testing in tertiary hospitals, rising medical tourism in countries such as Thailand and Singapore and increased local manufacturing of ultrasound systems by companies such as Mindray. Government health reforms and expanding insurance coverage are improving access to diagnostic services across the region.
India Pelvic Floor Diagnostics Market Size
India's pelvic floor diagnostics market is estimated at US$ 56 million in 2026. The country has a large and aging population, with the United Nations Population Fund (UNFPA) India Ageing Report 2023 projecting that people aged 60 and older are likely to make up more than 20% of the population by 2050. High birth rates in some regions, frequent home deliveries in rural areas and limited postpartum care contribute to a substantial burden of pelvic floor disorders, many of which remain undiagnosed. Awareness is rising through women's health campaigns and professional organizations such as the Indian Urogynecology Society.
Private hospital chains and urban diagnostic centers are investing in ultrasound and urodynamic equipment, while government schemes such as Ayushman Bharat are expanding insurance coverage. Lower-cost ultrasound systems, training programs for clinicians and growing physiotherapy networks create significant opportunities for market expansion.
Japan Pelvic Floor Diagnostics Market Size
Japan’s market is estimated at US$ 121 million in 2026. The country has one of the world's oldest populations, with about 29% of citizens aged 65 or older according to the Ministry of Internal Affairs and Communications. A nationwide epidemiological survey conducted by the Japanese Continence Society found that about 12% of adults aged 40 and older experience overactive bladder symptoms, and urinary incontinence is common among older women.
Japan's universal health insurance system covers urodynamic studies and imaging, and the country has high availability of advanced imaging, with more than 50 MRI units per million people according to the OECD. Leading domestic manufacturers such as Canon Medical Systems and FUJIFILM support ultrasound innovation. Demand for geriatric continence care, home-based monitoring, and less invasive diagnostic methods creates strong opportunities for suppliers.
Southeast Asia Pelvic Floor Diagnostics Market Size
Southeast Asia’s pelvic floor diagnostics market is estimated at US$ 46 million in 2026. Thailand has become an aged society with about one-fifth of its population aged 60 or older, while Singapore reports that around 19% of its resident population is aged 65 or older according to the Department of Statistics Singapore. Rising life expectancy, high birth volumes in countries such as Indonesia, the Philippines and Vietnam, and growing awareness of women's health are increasing demand for pelvic floor assessment.
Private hospitals in Singapore, Thailand and Malaysia offer advanced urogynecology services and attract medical tourists, supporting investment in urodynamic systems and 3D ultrasound. However, access remains limited in rural areas. Expanding national health insurance programs, training partnerships with international societies such as IUGA and the adoption of affordable portable ultrasound devices create opportunities for diagnostic equipment suppliers.

Competitive Landscape
The global pelvic floor diagnostics market is moderately fragmented, combining large imaging companies with specialized urodynamics and gastrointestinal diagnostics manufacturers. Imaging leaders such as GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems and Mindray supply ultrasound and MRI systems used in pelvic floor assessment, while specialists including Laborie Medical Technologies, Medtronic, Andromeda Medizinische Systeme, Medspira, Diversatek Healthcare and The Prometheus Group focus on urodynamics, anorectal manometry and electromyography.
Leaders differentiate through dedicated pelvic floor transducers, high-resolution sensors, user-friendly software, integration with electronic health records and strong clinical training programs.
R&D focuses on wireless and ambulatory urodynamics, AI-assisted ultrasound measurements and less invasive testing. Strategies include acquisitions to broaden pelvic health portfolios, partnerships with professional societies and expansion into Asia Pacific. Emerging business models emphasize service contracts, consumables such as catheters and sensors, and software subscriptions for reporting and data analytics.
Key Industry Developments
- In July 2025, an Italian research team highlighted MRI defecography (MRD) as an advanced imaging approach for pelvic floor dysfunction. The technique enables dynamic assessment of the pelvic floor and evaluation of multiple compartments, supporting more comprehensive diagnosis and treatment planning.
- In March 2026, Northern Health opened a new anorectal physiology laboratory to provide specialized testing and assessment for patients with pelvic floor dysfunction, strengthening diagnostic capabilities for anorectal disorders.
Companies Covered in Pelvic Floor Diagnostics Market
- Laborie, Inc.
- Medtronic plc
- The Prometheus Group
- Medspira LLC
- Diversatek, Inc.
- SRS Medical
- MEDKONSULT Medical Technology
- Alacer Biomedica
- Cadwell Industries, Inc.
- HC Italia Srl
- Neurosoft
- Noraxon USA, Inc.
- THD S.p.A.
- CooperSurgical, Inc.
Frequently Asked Questions
The global pelvic floor diagnostics market is expected to be valued at US$ 2.2 billion in 2026 and is projected to reach US$ 3.2 billion by 2033, expanding at a CAGR of 5.7% during the forecast period.
Demand is driven by the rising prevalence of urinary incontinence, pelvic organ prolapse and fecal incontinence in aging populations, childbirth-related pelvic floor injuries, expanding postpartum care programs and stricter preoperative evaluation following mesh safety reviews.
North America is likely to lead the market with around 36% share in 2026, supported by high disease awareness, established reimbursement for urodynamic and imaging procedures and a large network of specialized urogynecologists.
Next-generation wireless and ambulatory urodynamic systems, AI-enabled pelvic floor ultrasound and portable imaging integrated with postpartum and digital women's health services present the most significant opportunities through 2033.
Key players include Laborie Medical Technologies, Medtronic plc, GE HealthCare, Siemens Healthineers, Philips, Canon Medical Systems, Mindray, Andromeda Medizinische Systeme, Medspira LLC and Diversatek Healthcare.




